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Single-donor dominance is observed in the majority of patients following double-unit cord blood trans-
plantation (dCBT); however, the biological basis for this outcome is poorly understood. To investigate the
possible inﬂuence of speciﬁc cell lineages on dominance in dCBT, ﬂow cytometry assessment for CD34þ,
CD14þ, CD20þ, CD3CD56þ, CD3þCD56þ (natural killer), and T cell subsets (CD4þ, CD8þ, memory, naïve, and
regulatory) was performed on individual units. Subsets were calculated as infused viable cells per kilogram of
recipient actual weight. Sixty patients who underwent dCBT were included in the ﬁnal analysis. Higher CD3þ
cell dose was statistically concordant with the dominant unit in 72% of cases (P ¼ .0006). Further T cell
subset analyses showed that dominance was correlated more with the naive CD8þ cell subset (71% concor-
dance; P ¼ .009) than with the naive CD4þ cell subset (61% concordance; P ¼ .19). These data indicate that
a greater total CD3þ cell dose, particularly of naïve CD3þCD8þ T cells, may play an important role in deter-
mining single-donor dominance after dCBT.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION single-unit donor dominance. An extended immunopheno-
Cord blood (CB) transplantation (CBT) is an accepted
treatment for adults and children with hematologic malig-
nancies [1,2]. To overcome the limited cell doses that can be
provided by a single CB graft and more reliably achieve
sustained donor engraftment, double-unit CBT (dCBT) is
commonly performed in adult and larger adolescent patients
[3,4]. Interestingly, in the vast majority of dCBT recipients,
only one unit emerges as the source of long-term hemato-
poiesis [1,2,5]; however, the factors that determine which of
the 2 units will achieve single-donor dominance after dCBT
remain poorly understood.
Unit parameters, such as total nucleated cell (TNC) and
CD34þ cell doses, viability, degree of HLA matching, and
order of infusion, have not been uniformly associated with
donor dominance [6-8]. Conversely, CD3þ cell dose is
emerging as a reliable predictor of single-donor dominance
[9-11]. Indeed, a report from our institution presented the
ﬁrst direct evidence that only effector Tcells derived from the
dominant unit produce IFN-g in response to cells derived
from the nonengrafting unit [12]. More recently, we also
provided strong evidence indicating that the unit with
greater CD3 chimerism at day 7 is more likely to be the
dominant unit [13].
In the present study, we further investigated the associ-
ation between infused CD3 cell dose, along with possible
correlations of speciﬁc T cell subsets (CD3þ/CD8þ, CD3þ/
CD4þ, naïve/memory, and regulatory), and the emergence ofsentation at the 53rd Annual American
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12.09.004typing ﬂow cytometry panel was performed on a sample
obtained from each CB unit just before infusion in 72
consecutive patients undergoing dCBT for hematologic
malignancies. Infused cell doses were calculated and used to
investigate whether any speciﬁc T cell subsets were also
highly correlated with single-donor dominance.
METHODS
Patient/Donor Characteristics
Between January 2008 and May 2011, 72 patients received a dCBT at our
institution. Twelve patients (17%) were excluded because they either died
before obtaining informative chimerism data or had primary/secondary
graft failure. In accordance with institutional priority, patients received
a CBT if they lacked an available HLA-compatible related or matched
unrelated donor. All patients received unrelated donor CB grafts, whichwere
4/6- to 6/6-matched at HLA-A, -B, and -DRB1 antigens. HLA typing was
performed at the antigen level for HLA-A and -B, and high-resolution HLA
typing was performed for HLA-DRB1 alleles. The individual CB units were at
least 3/6 HLA-A, -B, and -DRB1 matched to one another, and each contained
a minimum of 1.5  107 TNCs/kg. All study activities were approved by the
Fred Hutchinson Cancer Research Center Institutional Review Board, and all
participants provided written informed consent in accordance with the
principles of the Declaration of Helsinki.
Conditioning Regimens and GVHD Prophylaxis
Myeloablative conditioning consisted of cyclophosphamide 60 mg/kg
i.v. daily for 2 days, total body irradiation (TBI) 1320 or 1200 cGy, and ﬂu-
darabine 40 mg/m2 i.v. daily for 3 days. Eleven patients received ﬂudarabine
30mg/m2 i.v. daily for 5 days, treosulfan at 14 g/m2 i.v. daily for 3 days, and a
single fraction of TBI 200 cGy. Reduced-intensity conditioning consisted of
ﬂudarabine 40mg/m2 i.v. daily for 5 days, a single dose of cyclophosphamide
50 mg/kg i.v., and a single fraction of TBI 200 or 300 cGy. Graft-versus-host
disease (GVHD) prophylaxis consisted of cyclosporine A along with myco-
phenolatemofetil. Emergent GVHDwas treated at the physician’s discretion.
Cell Dose Analysis
All CB units were thawed and washed by centrifugation before being
resuspended in preparation for infusion. Units were infused sequentially
with an interval of <45 minutes between each infusion. A small aliquot was
removed from the ﬁnal product just before infusion for analysis. This sample
was then processed for measurement of TNCs and ﬂow cytometryTransplantation.
Table 1
Patient Characteristics (n ¼ 60)
Characteristic Value
Age, years, median (IQR) 38.3 (18.6-51.4)
Female sex, n (%) 30 (50)
Weight, kg, median (IQR) 72.0 (59.9-79.8)
Cytomegalovirus serostatus, n (%)
Positive 36 (60)
Negative 24 (40)
Transplant type, n (%)
Myeloablative 46 (77)
Nonmyeloablative 14 (23)
GVHD prophylaxis with cyclosporine/mycophenolate,
n (%)
60 (100)
Disease, n (%)
Acute lymphoblastic leukemia 18 (30)
Acute myelogenous leukemia 26 (44)
Myelodysplastic/myeloproliferative diseases 5 (8)
Chronic lymphocytic leukemia 4 (7)
Other 7 (11)
Donorerecipient sex match, n (%)
Matchematch 22 (37)
Matchemismatch 28 (47)
Mismatchemismatch 10 (16)
HLA disparity, n (%)*
4/6 þ 4/6 26 (43)
4/6 þ 5/6 9 (15)
4/6 þ 6/6 d
5/6 þ 5/6 13 (22)
5/6 þ 5/6 8 (14)
6/6 þ 6/6 4 (6)
Days to engraftment, median (IQR)y
Myeloablative 25 (19-31)
Nonmyeloablative 13 (7-18)
* HLA matching reﬂects the lowest HLA match of the 2 units.
y The day of neutrophil engraftment was deﬁned as the ﬁrst of 3
consecutive days of an absolute neutrophil count of 500/mL.
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negative) cell subsets were measured by multicolor ﬂuorescence-activated
cell sorting analysis and then expressed as infused cell subsets per kilo-
gram of actual recipient weight: stem/progenitors (CD34þ), monocytes
(CD14þ), B (CD20þ), natural killer (NK; CD3CD56þ), NKT (CD3þCD56þ), and
T cell subsets CD3þCD4þ, CD3þCD8þ, CD45RA/CD45ROþ (memory)
CD45RAþ/CD45RO (naïve), and CD4þCD25þCD127lo for regulatory T cells.
Data were used to calculate total cell subsets per kilogram of recipient
weight for each CB unit.
Chimerism Analysis
Analysis of host and CB unit chimerism was performed on ﬂow
cytometryesorted CD3þ, CD56þ, and CD33þ fractions of peripheral blood on
days 7, 14, 21, 28, 56, and 80 after transplantation. Whole bone marrow
chimerism analysis was performed on days 28, 56, and 80 after trans-
plantation. DNA chimerism analyses were performed by ampliﬁed fragment
length polymorphism (detection sensitivity, 1%-5%; range of accuracy, 5%)
[14]. Single-donor dominance was generally deﬁned as >95% single-unit-
derived cells in all fractions. In the rare case where the 2 CB units engrafted
long term, the unit contributing to >60% hematopoiesis was considered the
dominant one. Similarly, in patients who died before day 100, the dominant
unit was considered the unit contributing to >60% hematopoiesis at the
time of the last chimerism analysis.
Statistical Analysis
If the infused dose of a cell subset was not associated with subsequent
development of single-donor dominance, then the expected concordance
between the dominant unit and a higher or lower dose of that subset should
be the random chance of 50% (eg, coin ﬂip). Thus, a one-sample test of the
null hypothesis that a binomial proportion is equal to 0.5 was used to test
the pairwise association of concordance of the relatively higher cell subset
dose with unit dominance. Similarly, in a separate analysis, if there was no
association between cell dose and unit dominance, then the expected mean
difference in dose between winning and losing units should be zero.
Accordingly, a one-sample t test was used to test the null hypothesis that the
mean difference in cell dose betweenwinning and losing units was zero. The
Wilcoxon rank sum test was used to compare graft characteristics in
dominant and nondominant units.
RESULTS
Patient and Graft Characteristics
Sixty patients were included in the ﬁnal analysis. Patient,
transplantation, and graft characteristics are summarized in
Table 1. Conditioning regimens were myeloablative (MC) in
46 patients (77%) and nonmyeloablative (NMC) in 14
patients (23%). The median time to neutrophil engraftment
was 13 days (interquartile range [IQR], 7-18 days) after NMC
conditioning and 25 days (IQR, 19-31 days) after MC condi-
tioning. At dayþ28 posttransplantation, a dominant unit (as
deﬁned 60% chimerism) was identiﬁed in all recipients of
MC conditioning. In particular, in all but 1 patient complete
contribution from a single unit (as deﬁned 95% chimer-
ism) was seen, at a median time of 14 days (IQR, 14-21 days).
The only patient with persistent contribution from both
units, still present at 1 year posttransplantation, received
a treosulfan-based conditioning regimen and 2 6/6 HLA-
matched units. In contrast, NMC recipients initially had
mixed donorehost chimerism, and single-donor dominance
(deﬁned as 60% chimerism) was observed in only 4
patients at day þ28. The remaining 10 patients converted to
single-donor dominance at a median time of 56 days (IQR,
56-80 days) posttransplantation; however, 3 patients still
demonstrated signiﬁcant contributions from both units at
day þ80.
Among the 120 CB units given to these 60 patients, the
degree of matching was as follows: HLA-A, -B, and -DRB1
matched in 15 units;mismatched at 1 antigen in 44 units; and
mismatched at 2 antigens in 61 units. HLA mismatch was not
a critical factor affecting dominance. Indeed, in 6 cases (10%),
the CBunitwith the betterHLAmatch to the recipient became
the dominant unit, whereas in 9 (15%) cases, the unit with theworse HLA match became dominant. In the remaining cases,
both CB units had the same degree of HLA mismatch.
Inﬂuence of CD3 þ Cells on Determining the Dominant
Unit
No signiﬁcant differences were seen in the median pre-
thaw and postwash TNC and CD34þ cell doses and postwash
viability between dominant and nondominant CB units
(Table 2). For some patients, a sample was not obtained or
insufﬁcient material was available from each double CB unit
to enable a complete cell subset analysis on both CB units
(Table 3). Of the 60 patients in our cohort, 58 had a sufﬁcient
sample for analysis of CD3þ, CD4þ, and CD8þ cell doses. The
dominant engrafting unit was the unit with the higher CD3þ
dose in 42 patients (72%; P ¼ .0006), the unit with the
higher CD4þ dose in 41 patients (71%; P ¼ .002), and the
unit with the higher CD8þ dose in 45 patients (78%;
P < .0001). In the subset of 14 patients who received NMC,
the proportion of positive correlation was identical to that
in the whole cohort (CD3þ, 10 of 14 [71%]; CD4þ, 10 of 14
[71%]; CD8þ, 11 of 14 [78%]).
In a smaller cohort of 38 patients (28 withMC and 10with
NMC), further analysis of various CD4þ and CD8þ subsets
showed that only the naïve CD8þ cell dose was highly asso-
ciated with donor dominance (71%; P ¼ .009), whereas
memory CD8þ, memory CD4þ, and naïve CD4þ cell doses
were not signiﬁcantly correlated with the dominant unit
(Table 3). This association between a higher ratio of infused
cell dose and dominance was deﬁned as positive concor-
dance (Figure 1). As expected in CB products, the total CD8þ
cell dose was strongly correlated with the majority naïve
CD8þ fraction (R ¼ 0.90; Figure 2), supporting the concept
Table 2
Characteristics of the Dominant and Nondominant CB Units
Factor Dominant Unit (n ¼ 60) Nondominant Unit (n ¼ 60) P Value
TNCs  107/kg, median (IQR)* 2.4 (1.9-3.3) 2.4 (1.9-3.0) .18
TNCs  107/kg, median (IQR)y 2.0 (1.6-2.6) 1.9 (1.5-2.4) .15
CD34þ  106/kg, median (IQR)* 0.11 (0.07-0.15) 0.10 (0.06-0.15) .44
CD34þ  106/kg, median (IQR)y 0.12 (0.08-0.19) 0.11 (0.07-0.19) .32
Viability, %, median (IQR) 74.3 (66.5-81) 67.6 (63.2-77) .07
* Prethaw values.
y Postwash values.
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marker for infused naïve CD8 cells.
As an alternative approach to assessing cell subset asso-
ciations with single-unit dominance, the mean difference in
infused cell dose between dominant and nondominant units
was also analyzed. The results also showed statistically
signiﬁcant differences for CD3þ, CD8þ, CD4þ, naïve CD8þ,
and naïve CD4þ cell doses (Table 4).Association of Other Cell Subsets
Among the other cell types analyzed, only higher levels of
NKT cells (68%; P ¼ .02) and CD20þ cells (68%; P ¼ .02) were
also statistically signiﬁcantly correlated with donor domi-
nance (Table 3). However, the mean difference between the
dominant and nondominant units was statistically signiﬁ-
cant for NKT cells, but not for CD20þ cells (Table 4). Postwash
viability was suggestively concordant (62%; P ¼ .07),
whereas no statistically signiﬁcant associations with the
infused dose of monocytes, NKT cells, or regulatory T cells
were observed (Tables 3 and 4).
No signiﬁcant associations were found between prefreeze
or postwash infused dose of total cells or CD34þ cells and the
likelihood of being the dominant unit. Furthermore, there
was no association between the order of infusion and the
probability of becoming the long-term engrafting unit
(P ¼ .60; Table 3).4.00
Ratio of Total CD8 Between Dominant and Non- dominant UnitDISCUSSION
The absolute number of T cells infused with CB stem cell
grafts is relatively lower compared with that infused withTable 3
Cell Subset/Total Number of Patients in Whom Larger Infused Value Was in
Concordance with the Winning Unit/Total Number of Patients
Cell Fractions
(Number of Evaluable
Unit Pairs)
Units with Positive
Concordance,
n (%; 95% CI)
P Value
Total CD8 (58) 45 (78; 67-88) <.0001
Total CD3 (58) 42 (72; 61-84) .0006
Naïve CD8 (38) 27 (71; 57-85) .009
Total CD4 (58) 41 (71; 59-82) .002
CD20 (41) 28 (68; 54-83) .02
NKT (38) 26 (68; 54-83) .02
Viability postwash (60) 37 (62; 49-74) .07
TNC postwash (60) 35 (59; 46-71) .15
Naïve CD4 (38) 23 (61; 45-76) .19
Memory CD4 (38) 23 (61; 45-76) .19
CD34þ postwash (60) 34 (57; 44-69) .30
CD14 (57) 26 (46; 33-59) .51
NK (39) 18 (46; 31-62) .63
Order of infusion* 31 (53; 41-66) .60
CD34 prefreeze (58) 31 (53; 41-66) .60
TNC prefreeze (58) 32 (53; 36-70) .73
T regulatory (34) 18 (53; 36-70) .73
Memory CD8 (38) 19 (50; 34-66) 1.00
Values with a signiﬁcant correlation are represented in bold.
* Unit infused as ﬁrst.bone marrow or peripheral blood stem cell grafts. Never-
theless, this study provides evidence that an elevated CD8þ
cell content, particularly of the naïve CD3þCD8þ Tcell subset,
is an important predictor in determining which CB unit will
ultimately predominate. Similar to previous reports [9,10],
here high concordancewas observed between elevated CD3þ
cell content and establishment of single-donor dominance.
However, to our knowledge, this is the ﬁrst published study
reporting a signiﬁcant correlation between infused
CD3þCD8þ and CD3þCD4þ doses in the CB graft and the
emergence of single-donor dominance.
Furthermore, in this study, naïve CD8þ cell dose was
particularly highly associated with unit dominance. Thus, it
may be hypothesized that naïve CD8þ T cells in one CB unit
will be activated when that unit becomes exposed in vivo to
the allogeneic antigens expressed by the second CB unit.
Having a relatively higher content of those naïve CD8þ T cells
will give that unit an advantage in facilitating the ultimate
rejection of the second CB unit. This hypothesis is supported
by data from animal models and in vitro testing showing that
predominantly naïve T cells can mount an antiallogeneic
response and cause GVHD [15], whereas transplantation of
memory CD8þ and CD4þ cells does not result in GVHD
reactivity [16,17]. Similarly, our results suggest that higher
doses of memory CD4þ and CD8þ subsets do not appear to0.00
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it was not always possible to determine the CD8þ subtype
content for each unit, the high correlation between total
CD8þ and naïve CD8þ cells in CB units allows us to infer that
the higher infused dose of the naïve population in those
cases was responsible for determining the dominant unit.
Evaluation of the limited number of paired samples
available for the naïve T cell subset analyses did not indicate
a signiﬁcant statistical correlation between a higher naïve
CD4þ cell dose and the probability of becoming the dominant
unit. However, analysis of the results using the mean of
differences revealed a statistically signiﬁcantly elevated
content of naïve CD4þ cells in the dominant units. HLA
alloreactivity has been shown to be derived from both naïve
CD4þ and CD8þ subsets [18]; thus, this difference in mean
infused naïve CD4þ cell dose suggests a potential role for the
naïve CD4þ cells along with naïve CD8þ cells in inﬂuencing
single-unit dominance.
In support of additional immune-mediated mechanisms
determining single-unit dominance, we also found a higher
infused content of NKT and B cells in the ultimately
dominant CB unit. NKT cells can exhibit potent direct killing
activity, through both MHC-unrestricted and TCR-mediatedTable 4
Mean Difference in Infused Viable Cell Dose between Dominant and
Nondominant Units for Each Cell Subset
Cell Fraction Dose Mean Difference between
Dominant and Nondominant
Units (95% CI)
P Value
Total CD8  105/kg 5.96 (3.40 to 8.52) <.0001
Naïve CD8  105/kg 4.16 (1.35 to 6.97) .006
Total CD3  106/kg 1.44 (0.55 to 2.32) .002
Total CD4  106/kg 1.05 (0.41 to 1.70) .002
NKT  104/kg 1.23 (0.28 to 2.17) .02
Naïve CD4  105/kg 7.22 (0.54 to 13.91) .04
Viability postwash, % 3.72 (0.17 to 7.28) .04
CD20  105/kg 2.15 (0.88 to 5.18) .17
T regulatory  104/kg 2.06 (4.89 to 0.78) .16
TNC prefreeze  109/kg 0.11 (0.09 to 0.32) .26
CD34 postwash  106/kg 1.16 (1.18 to 3.51) .32
Memory CD8  104/kg 2.04 (3.45 to 7.52) .47
TNCs postwash  109/kg 0.001 (0.002 to 0.004) .39
CD34 prefreeze  106/kg 0.01 (0.02 to 0.05) .45
NK  105/kg 0.97 (2.71 to 4.65) .61
Memory CD4  104/kg 4.31 (8.95 to 17.56) .53
CD14  104/kg 2.17 (30.82 to 26.48) .88
Values with a signiﬁcant correlation are represented in bold.mechanisms, against different cell line targets [19]. Thus, it
is possible that higher NKT content also might inﬂuence the
emergence of single-donor dominance, speciﬁcally through
HLA-mismatched immune-mediated rejection responses
toward the other CB unit. Similarly, higher numbers of CD20þ
cells in allogeneic grafts have been associated with immune
reactions, such as increased development of chronic GVHD,
and better clinical outcomes [20]. These preliminary ﬁndings
need to be conﬁrmed in future studies, and a clinical analysis
is ongoing at our institution to better clarify the potential
roles played by NKT and CD20þ cells in dCBT.
In contrast to previously published reports, this study
demonstrated no statistically signiﬁcant associations
between the infused dose of total cells or CD34þ cells and the
dominant CB unit. Although viable CD34þ dose is reportedly
the most important factor in determining the unit that will
dominate [8], this was not observed in our study. The lack of
correlation reported here compared with the study by
Scaravandou et al. [8] may be related to differences in the
ﬂow cytometry methods used to assess CD34þ cell viability
after postthaw/postwash processing of the CB units.
The results presented in this study strengthen the
evidence suggesting that the basis for single CB unit
predominance is an immunologic-mediated rejection mech-
anism between the 2 CB units. However, other factors besides
infused cell dose likely play a role, such as speciﬁc HLA-
matching interactions between the residual host immune
system and the 2 CB donors, interactions between the 2 CB
units, the host bone marrow environment, and differences in
homing efﬁciencies [21], which also could affect which unit
will ultimately predominate. Larger studies supporting
multivariate analyses of the inﬂuence of host and graft char-
acteristics on the emergence of a dominant CB unit after dCBT
could improve unit selection criteria. Currently, unit selection
is based on HLA matching, followed by prefreeze TNC and/or
CD34þ levels. Our results, in concert with ﬁndings from
previous studies [9,10], support the concept that prefreeze
CD3þ and/or CD8þ measurements might further improve
these unit selection algorithms. Knowing the CD8þ cell dose
might be even more critical for clinical trials involving graft
manipulation. For example, in studies of CD34þ ex vivo
expansion [22] focused on simply reducing the time to
neutrophil engraftment, the unit with fewer CD8þ cells could
be chosen for processing, because it would have less likeli-
hood of long-term predominance.
In conclusion, in this study we have provided evidence
that higher Tcell content, particularly of the naïve CD3þCD8þ
T cell subset, is an important predictor of which CB unit will
ultimately predominate in dCBT recipients. The data support
immune-mediated mechanisms as the primary driver of
single-unit dominance. Having the ability to accurately
predict, before infusion, which CB unit will ultimately
become the dominant long-term engrafting unit may
have practical implications for optimal unit selection.
Furthermore, improved understanding of the determinants
of short-term and long-term engraftment after dCBT also has
implications for ex vivo graft manipulations, immune
reconstitution, and disease control.
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